- Lois et règlements
- eservices
-
Media Center
Hotline for Health Services for Displaced Lebanese 1787Hotline for the Patient Admission to Hospitals 01/832700COVID-19 Vaccine Registration Form covax.moph.gov.lbMoPH Hotline 1214
Are you a new member? Sign up now
close
OPDUALAG - - 1
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L01FY02 | BioTech | Nivolumab - 240mg/20ml, Relatlimab - 80mg/20ml | 12368 | 58125/1 | OPDUALAG | 1 | Injectable solution | Infusion | Pacific pharma | Catalent Indiana, LLC | USA | 764,283,658 L.L | 2.44 | E2 | Bristol-Myers Squibb Company | USA | 12/12/20 |